Furthermore, it was shown that gefitinib inhibits melanoma cell proliferation and invasion through the VEGF/AKT signaling pathway (Table 6) [116] and a selective inhibition of BRAF could lead to a feedback activation of EGFR that confers adaptive resistance to BRAF inhibitors in both BRAF-mutant colorectal cancer and melanoma. Here, EGFR is linked to melanoma.